A PAMPA study of the permeability-enhancing effect of new ceramide analogues

Chemistry and Biodiversity

Volumn 6, Issue 11, 2009, Pages 1867-1874

  Sinkó, Bálint ^a   Kökösi, József ^a   Avdeef, Alex ^b   Takács Novák, Krisztina ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b PION INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYL GROUP; CERAMIDE DERIVATIVE; CHLOROFORM; CIPROFLOXACIN; DODECANE; NIFEDIPINE; VERAPAMIL;

ARTIFICIAL MEMBRANE; BLOOD BRAIN BARRIER; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; GASTROINTESTINAL ABSORPTION; MEMBRANE PERMEABILITY; MEMBRANE TRANSPORT; PARALLEL ARTIFICIAL MEMBRANE PERMEABILITY ASSAY; PREDICTION; REPRODUCIBILITY;

ANTI-INFECTIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CERAMIDES; CHEMISTRY, PHARMACEUTICAL; CIPROFLOXACIN; EXCIPIENTS; MEMBRANES, ARTIFICIAL; NIFEDIPINE; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; REPRODUCIBILITY OF RESULTS; SOFTWARE; SOLVENTS; STRUCTURE-ACTIVITY RELATIONSHIP; VERAPAMIL;

EID: 72449193597     PISSN: 16121872     EISSN: 16121880     Source Type: Journal    
DOI: 10.1002/cbdv.200900149     Document Type: Conference Paper

References (19)

1. G. L. Amidon, H. Lennernäs, V. P. Shah, J. R. Crison, Pharm. Res. 1995, 12, 413.
2. M. Kansy, F. Senner, K. Gubernator, J. Med. Chem. 1998, 41, 1007.
3. F. Wohnsland, B. Faller, J. Med. Chem. 2001, 44, 923.
4. A. Avdeef, 'Absorption and Drug Development', Wiley-Interscience, New York, 2003, p. 117.
5. A. Avdeef, P. Artursson, S. Neuhoff, L. Lazarova, J. Gråsjö, S. Tavelin, Eur. J. Pharm. Sci. 2005, 24, 333.
6. A. Avdeef, M. Strafford, E. Block, M. P. Balogh, W. Chambliss, I. Khan, Eur. J. Pharm. Sci. 2001, 14, 271.
7. J. A. Ruell, K. L. Tsinman, A. Avdeef, Eur. J. Pharm. Sci. 2003, 20, 393.
8. K. Sugano, H. Hamada, M. Machida, H. Ushio, K. Saitoh, K. Terada, Int. J. Pharm. 2001, 228, 181.
9. L. Di, E. H. Kerns, K. Fan, O. J. McConnell, G. T. Carter, Eur. J. Med. Chem. 2003, 38, 223.
10. A. Avdeef, Expert Opin. Drug Metab. Toxicol. 2005, 1, 325.
11. B. W. Barry, 'Dermatological Formulations: Percutaneous Absorption', Dekker, New York, 1983.
12. M. Córdoba-Díaz, M. Nova, B. Elorza, D. Córdoba-Díaz, J. R. Chantres, M. Có rdoba-Borrego, J. Controlled Release 2000, 69, 357.
13. M. R. Prausnitz, S. Mitragotri, R. Langer, Nat. Rev. Drug Discovery 2004, 3, 115.
14. G. Ottaviani, S. Martel, P.-A. Carrupt, J. Med. Chem. 2006, 49, 3948.
15. J. Hadgraft, Eur. J. Pharm. Biopharm. 2004, 58, 291.
16. J. A. Bouwstra, P. L. Honeywell-Nguyen, G. S. Gooris, M. Ponec, Prog. Lipid Res. 2003, 42, 1.
17. B. J. Pettus, C. E. Chalfant, Y. A. Hannun, Biochim. Biophys. Acta 2002, 1585, 114.
18. S. V. Gonzalez, P. Carlsen, Eur. J. Org. Chem. 2007, 21, 3495.
19. S. V. Gonzalez, P. Carlsen, Tetrahedron Lett. 2008, 49, 3925.